.Attribute Medication, Posted online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) therapy of individuals along with HER2+ enhanced breast cancer cells and also energetic or even dependable brain metastases revealed regular intracranial activity and also wide spread effectiveness of T-DXd.